Stay updated on AVP-786 Efficacy in Alzheimer's Agitation Clinical Trial
Sign up to get notified when there's something new on the AVP-786 Efficacy in Alzheimer's Agitation Clinical Trial page.

Latest updates to the AVP-786 Efficacy in Alzheimer's Agitation Clinical Trial page
- CheckyesterdayChange DetectedAdded Revision: v3.3.4; removed Revision: v3.3.3.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe study locations were expanded with numerous added sites across US states (Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri, New York, Texas, Virginia) and international regions (Limburg; British Columbia; Quebec; Santiago Metropolitan; Columbia; Santander Department; Istria County; Heves County; Bratislava Region; Sobota; Brezovica; Andalusia; Balearic Islands; Valenciana, Comunitat), while several location entries were removed in this revision.SummaryDifference1%

- Check51 days agoChange DetectedThe page now shows Revision: v3.3.2, updated from v3.2.0. No study details or user-facing content appear to be affected.SummaryDifference0.0%

- Check58 days agoChange DetectedThe page no longer displays the general government operating status notice, and all trial-specific content (title, identifiers, eligibility criteria, locations, and study plan) remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check72 days agoChange DetectedThe AVP-786 study for agitation in Alzheimer's disease is terminated, with recruitment stopped and no participants currently being treated.SummaryDifference0.2%

- Check101 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference3%

Stay in the know with updates to AVP-786 Efficacy in Alzheimer's Agitation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AVP-786 Efficacy in Alzheimer's Agitation Clinical Trial page.